FALLOPIAN TUBE CANCER

This early-phase study tests a new drug called AI-061, which combines two immunotherapy agents (anti-PD-1 and anti-CTLA-4) into one treatment. The goal is to find the safest dose and see if it can shrink tumors in people with advanced cancers like melanoma, lung, and ovarian canc…

This study tested a combination of three drugs—nivolumab, bevacizumab, and rucaparib—in 72 people whose ovarian, fallopian tube, or peritoneal cancer had returned after standard treatment. The goal was to see if the drugs could shrink tumors and control the disease. Participants …

This study tests a combination of two drugs, ONC-392 and pembrolizumab, in 58 women with ovarian cancer that has stopped responding to platinum-based chemotherapy. The goal is to see if the combo can shrink tumors and control the disease. Participants must have a specific type of…

This study was designed to test an experimental drug called BAT8006 in people with ovarian cancer that stopped responding to platinum-based chemotherapy. The goal was to find the safest dose and see if the drug could shrink tumors. However, the study was withdrawn before any part…

This early-phase trial tests a new drug called IMGN151 in adults with certain gynaecological cancers that have come back. The study aims to find a safe dose and check for side effects. About 256 participants with recurrent endometrial, ovarian, fallopian tube, primary peritoneal,…

This study tests a new treatment called IMNN-001, a gene therapy that boosts the immune system, given together with standard chemotherapy for people newly diagnosed with advanced ovarian, fallopian tube, or primary peritoneal cancer. The goal is to see if the combination helps ke…

This study tests a new oral drug called sovilnesib in people with advanced high-grade serous ovarian cancer that no longer responds to platinum chemotherapy. The main goal is to find the best dose that is safe and effective. About 120 adults will take the pill daily, and research…

This early-phase trial tests a new treatment called FT536 for people with ovarian, fallopian tube, or primary peritoneal cancer that has come back. The treatment is given directly into the belly three times in one week, after a short course of chemotherapy to prepare the body. On…

This study tests a two-step treatment for women whose ovarian, peritoneal, or fallopian tube cancer has returned after initial chemotherapy. First, participants receive a combination of carboplatin (a standard chemo) and mirvetuximab soravtansine (a targeted drug that attacks can…

This study tests whether the immunotherapy drug nivolumab, alone or combined with ipilimumab, can shrink tumors in people with advanced clear cell carcinoma of the ovary, fallopian tube, peritoneum, or other organs. About 46 participants with recurrent or metastatic disease will …

This phase 2 study tested whether combining an experimental vaccine (DPX-Survivac) with an immunotherapy drug (pembrolizumab) and low-dose chemotherapy can shrink tumors in people with advanced ovarian, fallopian tube, or peritoneal cancer. The vaccine trains the immune system to…

This early-stage study tests an experimental drug called BL-M17D1 in 120 adults with advanced solid tumors that have a specific protein (HER2) or a HER2 gene change. The main goals are to check the drug's safety, find the right dose, and see if it shrinks tumors. Participants mus…

This study tests whether the drug bevacizumab (Avastin) can help control ovarian, fallopian tube, or primary peritoneal cancer that was still found during a second-look surgery. About 35 adults with advanced-stage cancer who already had standard chemotherapy and surgery will rece…

This study looks at whether taking a low dose of aspirin for two weeks before surgery can reduce early signs of cancer in the fallopian tubes. About 18 women having their tubes removed for non-cancer reasons will take aspirin and then have their tissue analyzed. The goal is to se…

This study looks at how to quickly identify depression in women with ovarian, peritoneal, or fallopian tube cancer. It compares a special support program with enhanced standard care to see which better improves quality of life. About 409 women on active cancer treatment are takin…

This pilot study tested whether a prehabilitation program is practical and helpful for women with advanced ovarian cancer who receive chemotherapy before surgery. The program aims to improve patients' strength and well-being before their operation. 22 women participated, and the …

This study tests a program called Journey Ahead that helps women with gynecologic cancers (like ovarian, endometrial, or cervical cancer) improve their coping and communication skills. About 30 women who have been diagnosed or had a recurrence in the past 5 years will take part. …

This study tests whether a reminder sent to doctors can increase the number of patients with suspicious ovarian masses who are referred to a gynecologic oncology specialist within 30 days. About 20 women with concerning imaging results will be included, and their referral rates w…

This study follows 100 women with breast or gynecological cancer to see if what they eat in the month before starting chemotherapy is linked to levels of a protein called hepcidin. Researchers will also check if hepcidin levels relate to how much of the planned chemo dose patient…